FDA clears first “interchangeable” Humira biosimilarBiosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA Share XFDA clears first “interchangeable” Humira biosimilarhttps://pharmaphorum.com/news/fda-clears-first-interchangeable-humira-biosimilar/
AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashAbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Share XAbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clashhttps://pharmaphorum.com/news/abbvies-qulipta-cleared-for-migraine-prevention-setting-up-biohaven-clash/
ObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantSwiss biopharma company ObsEva has filed its oral GnRH antagonist linzagolix for the treatment of uterine fibroids in Share XObsEva files uterine fibroid drug in US, chasing AbbVie, Myovanthttps://pharmaphorum.com/news/obseva-filed-uterine-fibroid-drug-in-us-chasing-abbvie-myovant/
AbbVie spies potential in Regenxbio eye disease gene therapyAbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share XAbbVie spies potential in Regenxbio eye disease gene therapyhttps://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
FDA firms up JAK inhibitor warnings after Xeljanz reviewThe FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings Share XFDA firms up JAK inhibitor warnings after Xeljanz reviewhttps://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/
AbbVie’s Rinvoq cleared in EU for atopic dermatitisThe FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has Share XAbbVie’s Rinvoq cleared in EU for atopic dermatitishttps://pharmaphorum.com/news/abbvies-rinvoq-is-first-jak-drug-cleared-in-eu-for-atopic-dermatitis/
FTC drops AbbVie antitrust case, but fires a parting shot at the firmAbbVie will not be pursued any further by the US government over allegations that it used ‘sham’ litigation Share XFTC drops AbbVie antitrust case, but fires a parting shot at the firmhttps://pharmaphorum.com/news/ftc-drops-abbvie-antitrust-case-but-fires-a-parting-shot-at-the-firm/
AbbVie, Calico raise their age-related disease alliance funding to $3.5bnAbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases Share XAbbVie, Calico raise their age-related disease alliance funding to $3.5bnhttps://pharmaphorum.com/news/abbvie-calico-raise-their-age-related-disease-alliance-funding-to-3-5bn/
Allergan builds case for first drug therapy for presbyopiaIf you are in middle aged and find you have to hold your phone at arm’s length to Share XAllergan builds case for first drug therapy for presbyopiahttps://pharmaphorum.com/news/allergen-builds-case-for-first-drug-therapy-for-presbyopia/
